Sanofi has agreed a €45 per share cash deal to acquire Ablynx NV, representing a total deal value of about €3.9bn. The Belgian firm has accepted the offer, after rejecting bids from the Danish diabetes and hemophilia therapy maker Novo Nordisk AS over the past few weeks. Novo's most recent disclosed all-cash bid was worth €2.6bn, 50% lower than Sanofi's. (Also see "Novo Nordisk Offers €2.6bn For Ablynx" - Scrip, 8 January, 2018.)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?